News-Medical.Net August 5, 2024
On July 29, 2024, the U.S. FDA approved Alpha Cognition Inc.’s ALPHA-1062 (Zunveyl®), an Acetylcholinesterase (AChE) inhibitor, for treating mild-to-moderate Alzheimer’s disease. This condition affects approximately 6.7 million people in the United States. Over 70 % of physicians are dissatisfied with current therapies due to side effects and limited efficacy, with over 50 % of patients discontinuing treatment within a year. As research on AChEIs advances, the importance of ALPHA-1062 and similar molecules as therapeutic options for neurodegenerative disorders becomes increasingly evident.
Mechanism of action
Acetylcholinesterase (AChE) breaks down the neurotransmitter acetylcholine into choline and acetate at synaptic junctions. This process is crucial for terminating synaptic transmission, especially at neuromuscular junctions and cholinergic synapses in the nervous system. AChE’s mechanism...
Today's Sponsors
Today's Sponsor